Role of IL28B polymorphisms in patients with chronic hepatitis C genotype 2 or 3 treated with peginterferon alfa-2A and Ribavirin
TM Scherzer, AF Staettermayer, C Willheim, P Steindl-Munda, H Hofer, H Kerschner, HH Kessler, P Ferenci · Zeitschrift für Gastroenterologie · 2010 · Heft 05
Bibliografische Angaben
Zusammenfassung
Background and Aim: Polymorphisms of the IL28B-gene (rs12979860 and rs8099917) are associated with high sustained virological response (SVR) rates in HCV genotype 1 patients. This study analyses the impact of these IL28B polymorphisms on early treatment response (week 2 and 4) and on SVR in HCV genotype 2/3 patients. Methods: DNA was obtained from 84 HCV genotype 2/3 pts who participated in a randomized study comparing 400mg with 800mg ribavirin/day in combination with 180µg/week peginterferon alfa-2a. rs12979860 and rs8099917 were analyzed by StepOnePlus Real time PCR System. Virological response, including HCV…
